Clinical Trials Logo

Gaucher's Disease Type I clinical trials

View clinical trials related to Gaucher's Disease Type I.

Filter by:
  • None
  • Page 1

NCT ID: NCT06143904 Completed - Clinical trials for Gaucher's Disease Type I

A Study to Evaluate Absolute Bioavailability, Absorption, Metabolism, and Excretion of Genz-112638 in Healthy Male Participants

Start date: June 3, 2009
Phase: Phase 1
Study type: Interventional

Objectives: To determine pharmacokinetic (PK) variables, including absolute bioavailability (F), of Genz-99067, the free base of the L-tartaric acid salt of Genz-112638 as it exists in plasma, after a single intravenous (IV) dose and after a single oral dose of Genz-112638 (unlabeled). To determine the PK, total recovery, routes and rates of excretion, and the metabolic profile of Genz-99067 after 5 days of BID oral dosing with unlabeled Genz-112638 followed by a single dose of [14C]-Genz-112638.

NCT ID: NCT03485677 Active, not recruiting - Clinical trials for Gaucher's Disease Type III

Safety and Efficacy of Eliglustat With or Without Imiglucerase in Pediatric Patients With Gaucher Disease (GD) Type 1 and Type 3

ELIKIDS
Start date: April 11, 2018
Phase: Phase 3
Study type: Interventional

Primary Objective: Evaluate the safety and pharmacokinetics of eliglustat in pediatric patients (≥2 to <18 years old). Secondary Objective: Evaluate the efficacy of eliglustat and quality of life in pediatric patients (≥2 to <18 years old).